Clinical Biological and Pharmacological Factors Influencing Stroke Outcome (BIOSTROKE)

Principal Investigator

Régis Bordet
Department of Pharmacology,
University of Lille,
U1171, 59045 Lille, France.


Country France
Principal Investigator Régis Bordet
Contact person (email)
Key publication/reference Ducroquet et al. Stroke 2013;44:2324-2326 NCT00763217
Years in which study conducted 2005-2015
Size 477 included patients/210 patients reviewed or assessed by phone at 5 years
Population: Hospital/community Hospital
Selection: consecutive/random Consecutive
Admit with previous stroke? Yes
Admit with TIA? Yes
Age range 53-80
Number of centres 1
Control group: number, population, selection No
Initial: Time and data collected/tests administered Within 7 days: MedHx, VRF, MRI, plasma analysis, MMSE, IQCODE, CT
Detailed (initial)
Subsequent (follow-ups) 3m: function, IQCODE, MMSE
5 years: extensive NΨ; biological samples
Stroke-related data NIHSS , TOAST 
Functional tests/data Modified Rankin Scale, Barthel Index
Other medical tests/data Plasma biomarkers (vascular, inflammation, trophic factors, AD markers); DNA
Neuropsychological tests Test battery, MoCA
MRI scans, when and how many Initial, 5 year
PET scans No
Psychiatric exams/diagnoses Depression  (CES-D), apathy (Lille Apathy Rating Scale), anxiety (Hamilton Anxiety Scale), fatigue
Intervention trialled? No

CT=computed tomography scan, MedHx=medical history, VRF=vascular risk factors (hypertension, diabetes, atrial fibrillation, obesity, smoking etc.), NΨ=neuropsychological, TIA=transient ischemic attack, m=month, y=year